The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility ...

Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) saw its price target increased by Leerink Partners from €113.00 to €120.00, while the firm maintained an Outperform rating on the company's shares. Currently ...

French multinational pharmaceutical and healthcare firm Sanofi has completed a £1.4 billion buy-in for its pension scheme.

Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a large ...

The FDA issues a warning letter to Sanofi over manufacturing violations at its Massachusetts site, citing contamination and ...

French pharma major Sanofi (Euronext: SAN) has met analyst estimates for its fourth-quarter 2024 profit and confirmed plans for a 5 billion euro ($5.5 billion) share buyback program in 2025. The ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Sanofi SAN1.73%increase; green up pointing triangle forecast stronger earnings growth this year and said it planned to launch a $5.2 billion share buyback. The French pharmaceutical company said ...

Analyst Graham Parry of Bank of America Securities reiterated a Buy rating on Sanofi (SNYNF – Research Report), boosting the price target to ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, maintained the Buy rating on Sanofi (SNYNF – Research Report). The associated price target ...

The bulk annuity transaction for the scheme has fully secured the benefits of 4,900 retirees and 5,600 deferred members. The ...

Sanofi Pension Scheme has completed a £1.4bn (€1.7bn) buy-in securing the benefits of 4,900 retirees and 5,600 deferred ...